(Q36829847)

16 August 2017

1 reference

title

Molecularly targeted therapy for malignant glioma (English)

1 reference

16 August 2017

3

Annick Desjardins

1 reference

16 August 2017

2

David A Reardon

1 reference

16 August 2017

6

Jeremy N Rich

1 reference

16 August 2017

Sith Sathornsumetee

1

1 reference

16 August 2017

Jennifer A Quinn

series ordinal

4

1 reference

16 August 2017

James J Vredenburgh

series ordinal

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

12

1 reference

inferred from page(s)

published in

Cancer

1 reference

16 August 2017

110

1 reference

16 August 2017

13-24

1 reference

16 August 2017

1

1 reference

EGFR tyrosine kinase domain mutations in human gliomas

16 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

New treatment strategies for malignant gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Prognostic impact of molecular markers in a series of 220 primary glioblastomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase II trial of gefitinib in recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Will kinase inhibitors have a dark side?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Reduced glioma infiltration in Src-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Modulation of radiation response by histone deacetylase inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

The ubiquitin-proteasome pathway and its role in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Strategies for optimizing combinations of molecularly targeted anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Combining radiotherapy and angiogenesis inhibitors: clinical trial design

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Identification of human brain tumour initiating cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22741

7 January 2021

Identifiers

DOI

10.1002/CNCR.22741

1 reference

16 August 2017

1 reference